DM
ATYR

Deerfield Management’s aTyr Pharma ATYR Stock Holding History

Deerfield Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-32,966
Closed -$4.74M – 126
2015
Q3 		$4.74M Hold
32,966
– – 0.18% 91
2015
Q2 		$8.55M Buy
+32,966
New +$10.2M 0.28% 77

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RCM
Riverhead Capital Management Wilmington, Delaware $2.71B AUM 2.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Deerfield Management's ATYR Position: Q4 2015 in Review

Deerfield Management sold out of aTyr Pharma (ATYR) in Q4 2015, closing a stake of 32,966 shares — an estimated $4.74M sold.

Deerfield Management first reported a position in ATYR in Q2 2015 and held it in 2 quarters. The position peaked at $8.55M in Q2 2015. 50 funds tracked by Wall St. Rank hold ATYR as of Q4 2015.

  • Deerfield Management reported no remaining aTyr Pharma position as of Q4 2015 after selling out during the quarter.
  • Deerfield Management sold 32,966 aTyr Pharma shares in Q4 2015, an estimated $4.74M.
  • Deerfield Management first reported a position in aTyr Pharma in Q2 2015 and held it in 2 quarters.
  • Deerfield Management's aTyr Pharma position peaked at $8.55M in Q2 2015.
  • 50 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2015.

Based on Deerfield Management's 13F filing for Q4 2015, filed 16 Feb 2016.